Table 1.
Patient characteristics- univariate analyses.
| Total (n=123) | Hemorrhage (n=30) | No Hemorrhage (n=93) | p-value* | |
|---|---|---|---|---|
| Age (years (SD)) | 63 (17) | 67 (16) | 62 (18) | 0.19 |
| Gender (N (% female)) | 66 (54%) | 18 (60%) | 48 (52%) | 0.53 |
| Race (N (% African-American)) | 54 (44%) | 16 (53%) | 38 (41%) | 0.29 |
| Stroke Type (N (% embolic)) Watershed N= 8 Large Vessel Stenosis N= 6 Lacunar N= 1 Septic Embolization N= 2 Dissection N= 18 Vasculitis N=1 Other N= 22 |
65 (53%) | 16 (53%) | 49 (53%) | 1.00 |
| NIH Stroke Scale Score (mean (SD)) | 9 (7) | 11 (6) | 8 (7) | 0.033 |
| Antiplatelet Agent on Admission (N (%)) | 43 (35%) | 13 (45%) | 30 (32%) | 0.28 |
| Anticoagulation on Admission (N (% coumadin)) | 20 (16%) | 6 (20%) | 14 (15%) | 0.57 |
| LDL (mean mg/dL (SD)) | 86 (39) | 79 (42) | 88 (38) | 0.29 |
| Renal Failure (N (% eGFR <60mL/min/1.73m2)) | 42 (34%) | 15 (50%) | 27 (29%) | 0.046 |
| eGFR (mean (SD)) | 50.5 (16) | 45.1 (19) | 52.0 (15) | 0.035 |
| Diabetes (N (%)) | 37 (30%) | 10 (33%) | 27 (29%) | 0.65 |
| Peak Systolic Blood Pressure (mean mmHg (SD)) | 176 (29) | 179 (28) | 175 (30) | 0.53 |
| Peak Diastolic Blood Pressure (mean mmHg (SD)) | 98 (16) | 97 (13) | 98 (17) | 0.74 |
| Days SBP >180mmHg (mean days (SD)) | 2 (4) | 2 (3) | 2 (4) | 0.89 |
| Indication for Anticoagulation (N (% afib)) | 46 (37%) | 14 (47%) | 32 (34%) | 0.28 |
| Anticoagulated (N (%)) | 99 (80%) | 25 (83%) | 74 (80%) | 0.79 |
| Days from stroke to initiation of anticoagulation (mean days (SD)) | 8 (12) | 8 (7) | 8 (13) | 0.93 |
| Peak INR (mean (SD)) | 2.5 (2.0) | 2.3 (1.8) | 2.5 (2.0) | 0.61 |
| Peak PTTr (mean (SD)) | 3.1 (2.4) | 2.8 (1.8) | 3.2 (2.6) | 0.46 |
| Days Supratherapeutic (mean days (SD)) | 2 (4) | 2 (3) | 2 (4) | 0.53 |
| GRE Positive (N/80 (%)) | 48 (61%) | 10 (71%) | 38 (58%) | 0.55 |
| Other Bleeding (N (%)) | 9 (7%) | 4 (13%) | 5 (5%) | 0.22 |
| tPA (N (%)) | 18 (15%) | 8 (27%) | 10 (11%) | 0.41 |
*
p-values evaluate differences between hemorrhage and no hemorrhage patients.